ALPS
NASDAQALPS Group Inc
$1.00+0.03 (+3.51%)
News25/Ratings0
Price$1.00+0.01 (+0.55%)
2026-01-212026-04-24
News · 26 weeks21-62%
2025-11-022026-04-26
Mix1690d
- Insider9(56%)
- SEC Filings4(25%)
- Other2(13%)
- Leadership1(6%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Lee Hee Hang3 - Alps Group Inc (0002025774) (Issuer)
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- PRAlps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets OversightKUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a biotechnology research and healthcare platform focused on predictive, preventive, and precision medicine, announced the appointment of Mr. Hee H. Lee ("Mr. Lee") to its Board of Directors (the "Board"), effective April 17, 2026. The Company's Board will increase from five (5) to six (6) directors in connection with this appointment. Mr. Lee is considered independent under applicable Nasdaq rules and is expected to serve as a member of the Audit Committee and the Compensation Committee. Mr. Lee has over 35 years of exper
- INSIDERSEC Form 3 filed by new insider Poh Chit Laa3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chua Boon Ping3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chew Yoke Ling3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cheing Lye-Ping3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mohamed Suleiman Bin3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Manickam Ravichandran3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Low Wei Sim3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Tham Seng Kong3 - Alps Group Inc (0002025774) (Issuer)
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- PRAlps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture ProtocolKUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports. The publication reports findings from nine patients who received autologous Natural Killer (NK) cell infusions produced using the Company's in-house developed culture protocol. Natural Killer (NK) cells are a type of immune cell involved in the body's natural defense against abnormal cells.
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- PRAlps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome TherapyKUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a potential expansion of its exosome-related pipeline beyond its previously disclosed CELESOME(+) program. The announcement follows the publication of a preliminary retrospective clinical case series in SAGE Open Medical Case Reports describing nebulized human umbilical cord mesenchymal stem cell ("hUCMSC") derived exosome in patient with asthma and/or chronic obstructive pulmonar
- SECSEC Form 424B3 filed by ALPS Group Inc424B3 - Alps Group Inc (0002025774) (Filer)
- SECSEC Form EFFECT filed by ALPS Group IncEFFECT - Alps Group Inc (0002025774) (Filer)
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- PRAlps Group Inc Appoints Cheing Lye-Ping as Chief Financial OfficerKUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ:ALPS) (the "Company" or "Alps Group"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as ris
- SECSEC Form F-1 filed by ALPS Group IncF-1 - Alps Group Inc (0002025774) (Filer)
- SECSEC Form 20-F filed by Alpine Summit Energy Partners Inc.20-F - Alps Group Inc (0002025774) (Filer)
- SECAmendment: SEC Form 6-K/A filed by Alpine Summit Energy Partners Inc.6-K/A - Alps Group Inc (0002025774) (Filer)
- SECSEC Form CERT filed by Alpine Summit Energy Partners Inc.CERT - Alps Group Inc (0002025774) (Filer)
- SECSEC Form 6-K filed by Alpine Summit Energy Partners Inc.6-K - Alps Group Inc (0002025774) (Filer)